Claims for Patent: 9,096,681

Summary for Patent: 9,096,681

Title:	XBP1, CD138, and CS1 peptides
Abstract:	The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., a plasma cell disorder such as multiple myeloma or Waldenstrom\'s macroglobulinemia). The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
Inventor(s):	Munshi; Nikhil C. (Needham, MA), Anderson; Kenneth C. (Wellesley, MA), Bae; Jooeun (West Roxbury, MA)
Assignee:	Dana-Farber Cancer Institute, Inc. (Boston, MA)
Application Number:	12/995,661
Patent Claims:	1. A method for inducing an immune response in a subject having multiple myeloma, the method comprising administering to the subject a composition comprising: (a) a CS-1 peptide consisting of the amino acid sequence of SEQ ID NO:16, (b) an XBP-1 peptide consisting of the amino acid sequence of SEQ ID NO:6, (c) an XBP-1 peptide consisting of the amino acid sequence of SEQ ID NO:10, and (d) a CD138 peptide consisting of the amino acid sequence of SEQ ID NO:12. 2. The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier. 3. The method of claim 2, wherein the pharmaceutically acceptable carrier is one or more of a sterile diluent, an antibacterial agent, an antioxidant, a chelating agent, a buffer and an agent for the adjustment of tonicity. 4. The method of claim 3, wherein the sterile diluent comprises one or more of water for injection, saline solution, fixed oils, polyethylene glycol, glycerine, propylene glycol and other synthetic solvents. 5. The method of claim 1, wherein the composition further comprises one or more agents selected from therapeutic agents, diagnostic agents, prophylactic agents and immunostimulatory agents. 6. The method of claim 5, wherein the composition comprises one or more immunostimulatory agents. 7. The method of claim 6, wherein the one or more immunostimulatory agents comprises an adjuvant. 8. The method of claim 7, wherein the adjuvant is one or more of Freund's incomplete adjuvant, alum, a ligand for a Toll receptor, QS21, RIBI, mutant cholera toxin (MCT), and mutant E. coli heat labile toxin (MLT). 9. The method of claim 8, wherein the adjuvant comprises Freund's incomplete adjuvant. 10. The method of claim 8, wherein the adjuvant comprises a ligand for a Toll receptor. 11. The method of claim 1, wherein the subject is a human.

Details for Patent 9,096,681

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2028-06-02